IP Library › Granted Patent US 11,351,116
Granted Patent B2
US 11,351,116 · App. 16/049,777 · Granted Jun 7, 2022

Compositions and methods for treating skin conditions

Inventor: Sean Matthew Anderson (San Diego, CA)
A61K9/06A61K8/0291A61K8/064A61K8/25A61K8/26A61K8/37A61K8/73A61K8/731A61K8/735A61K8/8152A61K8/894A61K8/927A61K9/0014A61K9/1075A61K9/7015A61Q19/00A61Q19/007A61K2800/21A61K2800/49A61K2800/82
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,351,116
App. No.
16/049,777
Granted
Jun 7, 2022
Kind
B2
Abstract

Methods for forming dermatological compositions that deliver water and/or other hydrophilic compounds into or through the dermis using reverse micelles. The methods include forming compositions with an oil-based continuous phase and an emulsifier that form nanoparticle micelles. The nanoparticle micelles are formulated into biocompatible topical ointments that are stable at room temperature and can be distributed in consumer packaging and consumer distribution channels.

Claims (27)

1. A method for making a dermatological composition, comprising:

forming a dermatological precursor composition comprising (i) a biocompatible oil, (ii) an aqueous component including a humectant, emollient, or water-soluble active agent, (iii) an emulsifier having a molecular weight less than 2 kDa, wherein the concentration of the emulsifier in the biocompatible oil exceeds the critical micelle concentration, (iv) a film forming agent, and (v) a viscosity modifier; and

mixing the dermatological precursor composition with a sheer force sufficient to form a dermatological mixture comprising reverse micelles having a median particle size less than 800 nm in diameter.

2. The method of claim 1 , wherein the mixing is carried out using sonic homogenization.

3. The method of claim 1 , wherein the mixing is carried out to form reverse micelles with a median particle size of less than 500 nm.

4. The method of claim 1 , wherein the biocompatible oil includes lipid molecules with a carboxylic acid group, an ester group, and/or an ether group.

5. The method of claim 4 , wherein the biocompatible oil includes a lipid with a hydrocarbon chain length in a range from 8-20 carbons.

6. The method of claim 1 , wherein the emulsifier includes a nonionic compound.

7. The method of claim 1 , wherein the emulsifier includes a polysorbate, sorbitan, or a combination thereof.

8. The method of claim 1 , wherein the precursor composition includes a film forming agent.

9. The method of claim 8 , wherein the film forming agent includes a crosslinked siloxane formed by the reaction of an ethenyl-terminated siloxane and methylhydroxydimethyl siloxane in the presence of cyclomethicone.

10. The method of claim 1 , further comprising forming a topical skin emulsion comprising a cream, a foam, a paste, or a gel, the topical skin emulsion including at least a portion of the reverse micelles of claim 1 .

11. The method of claim 10 , further comprising stabilizing the reverse micelles in the topical skin emulsion using a preservative in sufficient quantity to stabilize the reverse micelles at room temperature for at least ten days and placing the topical skin emulsion in a consumer packaging.

12. The method of claim 1 , wherein the precursor includes a humectant comprising hyaluronan and the reverse micelles form with the hyaluronan in a hydrophilic component thereof.

13. The method of claim 12 , wherein the hyaluronan has a molecular weight in a range from 7,000-15,000 Daltons.

14. The method of claim 12 , wherein the hydrophilic component includes a water-soluble pharmaceutically active agent.

15. A method for making a dermatological composition, comprising:

forming a dermatological precursor composition comprising (i) a biocompatible oil, (ii) an aqueous component including a humectant, emollient, or water-soluble active agent, (iii) a film forming agent, and (iv) a non-ionic emulsifier having a molecular weight less than 2 kDa, wherein the concentration of the emulsifier in the biocompatible oil exceeds the critical micelle concentration;

mixing the dermatological precursor composition with sufficient sonic homogenization to form a mixture comprising reverse micelles in a continuous phase of the biocompatible oil, the micelles having a median particle size less than 500 nm in diameter;

forming a topical skin emulsion comprising a cream, a foam, a paste, or a gel, the topical skin emulsion including at least a portion of the reverse micelles.

16. The method of claim 15 , wherein:

the emulsifier includes polysorbate, sorbitan, or a combination thereof;

the precursor includes a hydrophilic component selected from a humectant, emollient, or water-soluble active agent; and

the film forming agent includes a crosslinked siloxane formed by the reaction of an ethenyl-terminated siloxane and methylhydroxydimethyl siloxane in the presence of cyclomethicone.

17. The method of claim 15 , wherein the biocompatible oil includes lipid molecules with a carboxylic acid group, an ester group, and/or an ether group and having a hydrocarbon chain length in a range from 8-20 carbons.

18. The method of claim 15 , wherein the precursor composition includes a humectant comprising hyaluronan with a molecular weight in a range from 7,000-15,000 Daltons, and the reverse micelles form with the hyaluronan in a hydrophilic component thereof.

19. A method for treating a skin condition, comprising identifying a patient with a skin condition and applying to the skin thereof the reverse micelles formed according to the method of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2018
From: ANDERSON, SEAN MATTHEW
To: AQUA REGENERATIVE THERAPIES LLC
Reel/Frame 046682/0100 →
Continuity (3)
Division 14923258 · Oct 26, 2015
Provisional Application 62068623 · Oct 24, 2014
Related Publication 20180333356A1 · Nov 22, 2018